Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody for various ophthalmic indications. The company has received marketing authorization for the product in the European Union and United Kingdom for the treatment of wet age-related macular degeneration. With promising clinical trial results and a strong market potential in Europe, the company has a positive outlook for potential FDA approval in the US and potential growth in commercial sales. Additionally, the company's proprietary formulation of bevacizumab could potentially replace compounded bevacizumab, leading to significant pricing and reimbursement advantages. However, the company needs to address the issues raised by the FDA in their Complete Response Letter and demonstrate a clear path to FDA approval for a more optimistic outlook.

Bears say

Outlook Therapeutics is currently facing various challenges and uncertainties, including potential approval roadblocks in the US, disappointing European unit sales, and the need for additional financing. These challenges could impact the company's potential revenue and profitability, and as a result, it is prudent to take a wait-and-see approach before considering a positive outlook on the stock. Furthermore, the company's recent quarterly results showed a higher-than-expected loss per share and a decrease in cash and cash equivalents, highlighting its financial struggles. Given these factors, it is logical to have a neutral stance on the stock for now.

OTLK has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 3 analysts, OTLK has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.